Advanced Glycation End-Products and Their Receptors: Related Pathologies, Recent Therapeutic Strategies, and a Potential Model for Future Neurodegeneration Studies

Chemical Research in Toxicology

Volumn 29, Issue 5, 2016, Pages 707-714

  Pinkas, Adi ^a   Aschner, Michael ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; EPALRESTAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUERCETIN;

ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; ENDOTHELIUM CELL; GENERAL PATHOLOGY; HUMAN; INFLAMMATION; MACROPHAGE; MONOCYTE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENICITY; PODOCYTE; PROTEIN PROTEIN INTERACTION; REVIEW; SMOOTH MUSCLE CELL; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES; THEORETICAL MODEL;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; CAENORHABDITIS ELEGANS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, THEORETICAL; NEURODEGENERATIVE DISEASES;

EID: 84969835498     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.6b00034     Document Type: Review

References (134)

1. Monnier, V. M. (1990) Nonenzymatic glycosylation, the Maillard reaction and the aging process J. Gerontol. 45, B105-111 10.1093/geronj/45.4.B105
2. Stevens, V. J., Rouzer, C. A., Monnier, V. M., and Cerami, A. (1978) Diabetic cataract formation: potential role of glycosylation of lens crystallins Proc. Natl. Acad. Sci. U. S. A. 75, 2918-2922 10.1073/pnas.75.6.2918
3. Schmidt, A. M., Hori, O., Brett, J., Yan, S. D., Wautier, J. L., and Stern, D. (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions Arterioscler., Thromb., Vasc. Biol. 14, 1521-1528 10.1161/01.ATV.14.10.1521
4. Singh, R., Barden, A., Mori, T., and Beilin, L. (2001) Advanced glycation end-products: a review Diabetologia 44, 129-146 10.1007/s001250051591
5. Brownlee, M. (1995) Advanced protein glycosylation in diabetes and aging Annu. Rev. Med. 46, 223-234 10.1146/annurev.med.46.1.223
6. Tanaka, S., Avigad, G., Brodsky, B., and Eikenberry, E. F. (1988) Glycation induces expansion of the molecular packing of collagen J. Mol. Biol. 203, 495-505 10.1016/0022-2836(88)90015-0
7. Rahbar, S., Blumenfeld, O., and Ranney, H. M. (1969) Studies of an unusual hemoglobin in patients with diabetes mellitus Biochem. Biophys. Res. Commun. 36, 838-843 10.1016/0006-291X(69)90685-8
8. Palimeri, S., Palioura, E., and Diamanti-Kandarakis, E. (2015) Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management Diabetes, Metab. Syndr. Obes.: Targets Ther. 8, 415-426 10.2147/DMSO.S63089
9. Ulrich, P. and Cerami, A. (2001) Protein glycation, diabetes, and aging Recent Prog. Horm. Res. 56, 1-21 10.1210/rp.56.1.1
10. Uribarri, J., Woodruff, S., Goodman, S., Cai, W., Chen, X., Pyzik, R., Yong, A., Striker, G. E., and Vlassara, H. (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet J. Am. Diet. Assoc. 110, 911-916 10.1016/j.jada.2010.03.018
11. Stern, D., Yan, S. D., Yan, S. F., and Schmidt, A. M. (2002) Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings Adv. Drug Delivery Rev. 54, 1615-1625 10.1016/S0169-409X(02)00160-6
12. Vlassara, H. and Uribarri, J. (2014) Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr. Diabetes Rep. 14, 453 10.1007/s11892-013-0453-1
13. OBrien, J. and Morrissey, P. A. (1989) Nutritional and toxicological aspects of the Maillard browning reaction in foods Crit. Rev. Food Sci. Nutr. 28, 211-248 10.1080/10408398909527499
14. Goldberg, T., Cai, W., Peppa, M., Dardaine, V., Baliga, B. S., Uribarri, J., and Vlassara, H. (2004) Advanced glycoxidation end products in commonly consumed foods J. Am. Diet. Assoc. 104, 1287-1291 10.1016/j.jada.2004.05.214
15. Schmidt, A. M., Yan, S. D., Wautier, J. L., and Stern, D. (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis Circ. Res. 84, 489-497 10.1161/01.RES.84.5.489
16. Schmidt, A. M., Hasu, M., Popov, D., Zhang, J. H., Chen, J., Yan, S. D., Brett, J., Cao, R., Kuwabara, K., and Costache, G. (1994) Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins Proc. Natl. Acad. Sci. U. S. A. 91, 8807-8811 10.1073/pnas.91.19.8807
17. Fu, M. X., Wells-Knecht, K. J., Blackledge, J. A., Lyons, T. J., Thorpe, S. R., and Baynes, J. W. (1994) Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction Diabetes 43, 676-683 10.2337/diabetes.43.5.676
18. Thornalley, P. J. (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs Cell. Mol. Biol. (Sarreguemines, Fr., Online) 44, 1013-1023
19. Chuyen, N. V. (2006) Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs Mol. Nutr. Food Res. 50, 1140-1149 10.1002/mnfr.200600144
20. Takeuchi, M., Takino, J., and Yamagishi, S. (2010) Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy J. Ophthalmol. 2010, 170393 10.1155/2010/170393
21. Busch, M., Franke, S., Ruster, C., and Wolf, G. (2010) Advanced glycation end-products and the kidney Eur. J. Clin. Invest. 40, 742-755 10.1111/j.1365-2362.2010.02317.x
22. Vlassara, H., Uribarri, J., Cai, W., and Striker, G. (2008) Advanced glycation end product homeostasis: exogenous oxidants and innate defenses Ann. N. Y. Acad. Sci. 1126, 46-52 10.1196/annals.1433.055
23. Karasu, C. (2010) Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment Open Cardiovasc. Med. J. 4, 240-256 10.2174/1874192401004010240
24. Cai, W., He, J. C., Zhu, L., Lu, C., and Vlassara, H. (2006) Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor Proc. Natl. Acad. Sci. U. S. A. 103, 13801-13806 10.1073/pnas.0600362103
25. Cai, W., Torreggiani, M., Zhu, L., Chen, X., He, J. C., Striker, G. E., and Vlassara, H. (2010) AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease Am. J. Physiol. Cell Physiol. 298, C624-634 10.1152/ajpcell.00463.2009
26. Uribarri, J., Cai, W., Ramdas, M., Goodman, S., Pyzik, R., Chen, X., Zhu, L., Striker, G. E., and Vlassara, H. (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1 Diabetes Care 34, 1610-1616 10.2337/dc11-0091
27. Schmidt, A. M., Hori, O., Cao, R., Yan, S. D., Brett, J., Wautier, J. L., Ogawa, S., Kuwabara, K., Matsumoto, M., and Stern, D. (1996) RAGE: a novel cellular receptor for advanced glycation end products Diabetes 45 (Suppl. 3) S77-80 10.2337/diab.45.3.S77
28. Ramasamy, R., Yan, S. F., and Schmidt, A. M. (2012) The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes Vasc. Pharmacol. 57, 160-167 10.1016/j.vph.2012.06.004
29. Kislinger, T., Fu, C., Huber, B., Qu, W., Taguchi, A., Du Yan, S., Hofmann, M., Yan, S. F., Pischetsrieder, M., Stern, D., and Schmidt, A. M. (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression J. Biol. Chem. 274, 31740-31749 10.1074/jbc.274.44.31740
30. Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2000) The biology of the receptor for advanced glycation end products and its ligands Biochim. Biophys. Acta, Mol. Cell Res. 1498, 99-111 10.1016/S0167-4889(00)00087-2
31. Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., Neurath, M. F., Slattery, T., Beach, D., McClary, J., Nagashima, M., Morser, J., Stern, D., and Schmidt, A. M. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides Cell 97, 889-901 10.1016/S0092-8674(00)80801-6
32. Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., Hofmann, M. A., Kislinger, T., Ingram, M., Lu, A., Tanaka, H., Hori, O., Ogawa, S., Stern, D. M., and Schmidt, A. M. (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases Nature 405, 354-360 10.1038/35012626
33. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A. M. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimers disease Nature 382, 685-691 10.1038/382685a0
34. Rai, V., Toure, F., Chitayat, S., Pei, R., Song, F., Li, Q., Zhang, J., Rosario, R., Ramasamy, R., Chazin, W. J., and Schmidt, A. M. (2012) Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling J. Exp. Med. 209, 2339-2350 10.1084/jem.20120873
35. Chavakis, T., Bierhaus, A., Al-Fakhri, N., Schneider, D., Witte, S., Linn, T., Nagashima, M., Morser, J., Arnold, B., Preissner, K. T., and Nawroth, P. P. (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment J. Exp. Med. 198, 1507-1515 10.1084/jem.20030800
36. He, M., Kubo, H., Morimoto, K., Fujino, N., Suzuki, T., Takahasi, T., Yamada, M., Yamaya, M., Maekawa, T., Yamamoto, Y., and Yamamoto, H. (2011) Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells EMBO Rep. 12, 358-364 10.1038/embor.2011.28
37. Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., and Simm, A. (2014) Role of advanced glycation end products in cellular signaling Redox Biol. 2, 411-429 10.1016/j.redox.2013.12.016
38. Vistoli, G., De Maddis, D., Cipak, A., Zarkovic, N., Carini, M., and Aldini, G. (2013) Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation Free Radical Res. 47 (Suppl. 1) 3-27 10.3109/10715762.2013.815348
39. Vlassara, H. and Palace, M. R. (2002) Diabetes and advanced glycation endproducts J. Intern. Med. 251, 87-101 10.1046/j.1365-2796.2002.00932.x
40. Ahmed, N. (2005) Advanced glycation endproducts - role in pathology of diabetic complications Diabetes Res. Clin. Pract. 67, 3-21 10.1016/j.diabres.2004.09.004
41. Bierhaus, A., Stern, D. M., and Nawroth, P. P. (2006) RAGE in inflammation: a new therapeutic target? Curr. Opin. Investig. Drugs 7, 985-991
42. Yonekura, H., Yamamoto, Y., Sakurai, S., Watanabe, T., and Yamamoto, H. (2005) Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury J. Pharmacol. Sci. 97, 305-311 10.1254/jphs.CPJ04005X
43. Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P. M., Chen, J., Hong, M., Luther, T., Henle, T., Kloting, I., Morcos, M., Hofmann, M., Tritschler, H., Weigle, B., Kasper, M., Smith, M., Perry, G., Schmidt, A. M., Stern, D. M., Haring, H. U., Schleicher, E., and Nawroth, P. P. (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB Diabetes 50, 2792-2808 10.2337/diabetes.50.12.2792
44. Ottum, M. S. and Mistry, A. M. (2015) Advanced glycation end-products: modifiable environmental factors profoundly mediate insulin resistance J. Clin. Biochem. Nutr. 57, 1-12 10.3164/jcbn.15-3
45. Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., Elliston, K., Stern, D., and Shaw, A. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins J. Biol. Chem. 267, 14998-15004
46. Hudson, B. I., Carter, A. M., Harja, E., Kalea, A. Z., Arriero, M., Yang, H., Grant, P. J., and Schmidt, A. M. (2008) Identification, classification, and expression of RAGE gene splice variants FASEB J. 22, 1572-1580 10.1096/fj.07-9909com
47. Maillard-Lefebvre, H., Boulanger, E., Daroux, M., Gaxatte, C., Hudson, B. I., and Lambert, M. (2009) Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases Rheumatology (Oxford, U. K.) 48, 1190-1196 10.1093/rheumatology/kep199
48. Yan, S. F., Ramasamy, R., and Schmidt, A. M. (2010) Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging Biochem. Pharmacol. 79, 1379-1386 10.1016/j.bcp.2010.01.013
49. Lanati, N., Emanuele, E., Brondino, N., and Geroldi, D. (2010) Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation Curr. Vasc. Pharmacol. 8, 86-92 10.2174/157016110790226642
50. Vlassara, H. and Striker, G. E. (2013) Advanced glycation endproducts in diabetes and diabetic complications Endocrinol. Metab. Clin. North Am. 42, 697-719 10.1016/j.ecl.2013.07.005
51. Goh, S. Y. and Cooper, M. E. (2008) Clinical review: The role of advanced glycation end products in progression and complications of diabetes J. Clin. Endocrinol. Metab. 93, 1143-1152 10.1210/jc.2007-1817
52. Tan, A. L., Forbes, J. M., and Cooper, M. E. (2007) AGE, RAGE, and ROS in diabetic nephropathy Semin. Nephrol. 27, 130-143 10.1016/j.semnephrol.2007.01.006
53. Chung, A. C., Zhang, H., Kong, Y. Z., Tan, J. J., Huang, X. R., Kopp, J. B., and Lan, H. Y. (2010) Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling J. Am. Soc. Nephrol. 21, 249-260 10.1681/ASN.2009010018
54. Coresh, J., Astor, B. C., Greene, T., Eknoyan, G., and Levey, A. S. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am. J. Kidney Dis. 41, 1-12 10.1053/ajkd.2003.50007
55. Hyogo, H. and Yamagishi, S. (2008) Advanced glycation end products (AGEs) and their involvement in liver disease Curr. Pharm. Des. 14, 969-972 10.2174/138161208784139701
56. Santos, J. C., Valentim, I. B., de Araujo, O. R., Ataide, R., and Goulart, M. O. (2013) Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products Int. J. Mol. Sci. 14, 19846-19866 10.3390/ijms141019846
57. Sebekova, K., Kupcova, V., Schinzel, R., and Heidland, A. (2002) Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation J. Hepatol. 36, 66-71 10.1016/S0168-8278(01)00232-X
58. Yagmur, E., Tacke, F., Weiss, C., Lahme, B., Manns, M. P., Kiefer, P., Trautwein, C., and Gressner, A. M. (2006) Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis Clin. Biochem. 39, 39-45 10.1016/j.clinbiochem.2005.07.016
59. Hyogo, H., Yamagishi, S., Iwamoto, K., Arihiro, K., Takeuchi, M., Sato, T., Ochi, H., Nonaka, M., Nabeshima, Y., Inoue, M., Ishitobi, T., Chayama, K., and Tazuma, S. (2007) Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis J. Gastroenterol. Hepatol. 22, 1112-1119 10.1111/j.1440-1746.2007.04943.x
60. Cai, W., He, J. C., Zhu, L., Chen, X., Wallenstein, S., Striker, G. E., and Vlassara, H. (2007) Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression Am. J. Pathol. 170, 1893-1902 10.2353/ajpath.2007.061281
61. Patel, R., Baker, S. S., Liu, W., Desai, S., Alkhouri, R., Kozielski, R., Mastrandrea, L., Sarfraz, A., Cai, W., Vlassara, H., Patel, M. S., Baker, R. D., and Zhu, L. (2012) Effect of dietary advanced glycation end products on mouse liver PLoS One 7, e35143 10.1371/journal.pone.0035143
62. Malik, P., Chaudhry, N., Mittal, R., and Mukherjee, T. K. (2015) Role of receptor for advanced glycation end products in the complication and progression of various types of cancers Biochim. Biophys. Acta, Gen. Subj. 1850, 1898-1904 10.1016/j.bbagen.2015.05.020
63. Fukami, K., Yamagishi, S., and Okuda, S. (2014) Role of AGEs-RAGE system in cardiovascular disease Curr. Pharm. Des. 20, 2395-2402 10.2174/13816128113199990475
64. Kandarakis, S. A., Piperi, C., Topouzis, F., and Papavassiliou, A. G. (2014) Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases Prog. Retinal Eye Res. 42, 85-102 10.1016/j.preteyeres.2014.05.002
65. Yamagishi, S. (2011) Role of advanced glycation end products (AGEs) in osteoporosis in diabetes Curr. Drug Targets 12, 2096-2102 10.2174/138945011798829456
66. Diamanti-Kandarakis, E., Piperi, C., Kalofoutis, A., and Creatsas, G. (2005) Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome Clin. Endocrinol. (Oxford, U. K.) 62, 37-43 10.1111/j.1365-2265.2004.02170.x
67. Diamanti-Kandarakis, E., Piouka, A., Livadas, S., Piperi, C., Katsikis, I., Papavassiliou, A. G., and Panidis, D. (2009) Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome Eur. J. Endocrinol. 160, 847-853 10.1530/EJE-08-0510
68. Pamplona, R., Ilieva, E., Ayala, V., Bellmunt, M. J., Cacabelos, D., Dalfo, E., Ferrer, I., and Portero-Otin, M. (2008) Maillard reaction versus other nonenzymatic modifications in neurodegenerative processes Ann. N. Y. Acad. Sci. 1126, 315-319 10.1196/annals.1433.014
69. Kuhla, A., Ludwig, S. C., Kuhla, B., Munch, G., and Vollmar, B. (2015) Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimers disease brain Neurobiol. Aging 36, 753-761 10.1016/j.neurobiolaging.2014.09.025
70. Ko, S. Y., Ko, H. A., Chu, K. H., Shieh, T. M., Chi, T. C., Chen, H. I., Chang, W. C., and Chang, S. S. (2015) The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimers Disease PLoS One 10, e0143345 10.1371/journal.pone.0143345
71. Salahuddin, P., Rabbani, G., and Khan, R. H. (2014) The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach Cell. Mol. Biol. Lett. 19, 407-437 10.2478/s11658-014-0205-5
72. Li, J., Liu, D., Sun, L., Lu, Y., and Zhang, Z. (2012) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective J. Neurol. Sci. 317, 1-5 10.1016/j.jns.2012.02.018
73. Juranek, J., Ray, R., Banach, M., and Rai, V. (2015) Receptor for advanced glycation end-products in neurodegenerative diseases Rev. Neurosci. 26, 691-698 10.1515/revneuro-2015-0003
74. Selkoe, D. J. (2001) Alzheimers disease: genes, proteins, and therapy Physiol. Rev. 81, 741-766
75. Apelt, J. and Schliebs, R. (2001) Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology Brain Res. 894, 21-30 10.1016/S0006-8993(00)03176-0
76. Dickson, D. W. (1997) The pathogenesis of senile plaques J. Neuropathol. Exp. Neurol. 56, 321-339 10.1097/00005072-199704000-00001
77. Arendt, T., Holzer, M., Stobe, A., Gartner, U., Luth, H. J., Bruckner, M. K., and Ueberham, U. (2000) Activated mitogenic signaling induces a process of dedifferentiation in Alzheimers disease that eventually results in cell death Ann. N. Y. Acad. Sci. 920, 249-255 10.1111/j.1749-6632.2000.tb06931.x
78. Kruman, I. I. (2004) Why do neurons enter the cell cycle? Cell Cycle 3, 769-773 10.4161/cc.3.6.901
79. Nagy, Z. (2000) Cell cycle regulatory failure in neurones: causes and consequences Neurobiol. Aging 21, 761-769 10.1016/S0197-4580(00)00223-2
80. Yang, Y., Geldmacher, D. S., and Herrup, K. (2001) DNA replication precedes neuronal cell death in Alzheimers disease J. Neurosci. 21, 2661-2668
81. Lee, J. J., Wang, P. W., Yang, I. H., Wu, C. L., and Chuang, J. H. (2015) Amyloid-beta mediates the receptor of advanced glycation end product-induced pro-inflammatory response via toll-like receptor 4 signaling pathway in retinal ganglion cell line RGC-5 Int. J. Biochem. Cell Biol. 64, 1-10 10.1016/j.biocel.2015.03.002
82. Liu, R., Wu, C. X., Zhou, D., Yang, F., Tian, S., Zhang, L., Zhang, T. T., and Du, G. H. (2012) Pinocembrin protects against beta-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis BMC Med. 10, 105 10.1186/1741-7015-10-105
83. Nenna, A., Spadaccio, C., Lusini, M., Ulianich, L., Chello, M., and Nappi, F. (2015) Basic and clinical research against Advanced Glycation End Products (AGEs): new compounds to tackle cardiovascular disease and diabetic complications Recent Pat. Cardiovasc. Drug Discovery 10, 10-33 10.2174/1574890110666151104120039
84. Hamada, Y., Odagaki, Y., Sakakibara, F., Naruse, K., Koh, N., and Hotta, N. (1995) Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients Life Sci. 57, 23-29 10.1016/0024-3205(95)00239-3
85. Hamada, Y., Nakamura, J., Naruse, K., Komori, T., Kato, K., Kasuya, Y., Nagai, R., Horiuchi, S., and Hotta, N. (2000) Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients Diabetes Care 23, 1539-1544 10.2337/diacare.23.10.1539
86. Kawai, T., Takei, I., Tokui, M., Funae, O., Miyamoto, K., Tabata, M., Hirata, T., Saruta, T., Shimada, A., and Itoh, H. (2010) Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine Journal of Diabetes and its Complications 24, 424-432 10.1016/j.jdiacomp.2008.10.005
87. Rahbar, S., Natarajan, R., Yerneni, K., Scott, S., Gonzales, N., and Nadler, J. L. (2000) Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation Clin. Chim. Acta 301, 65-77 10.1016/S0009-8981(00)00327-2
88. Tan, K. C., Chow, W. S., Tso, A. W., Xu, A., Tse, H. F., Hoo, R. L., Betteridge, D. J., and Lam, K. S. (2007) Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes Diabetologia 50, 1819-1825 10.1007/s00125-007-0759-0
89. Wang, K., Zhou, Z., Zhang, M., Fan, L., Forudi, F., Zhou, X., Qu, W., Lincoff, A. M., Schmidt, A. M., Topol, E. J., and Penn, M. S. (2006) Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model J. Pharmacol. Exp. Ther. 317, 37-43 10.1124/jpet.105.095125
90. Liang, C., Ren, Y., Tan, H., He, Z., Jiang, Q., Wu, J., Zhen, Y., Fan, M., and Wu, Z. (2009) Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products Br. J. Pharmacol. 158, 1865-1873 10.1111/j.1476-5381.2009.00450.x
91. Oz Gul, O., Tuncel, E., Yilmaz, Y., Ulukaya, E., Gul, C. B., Kiyici, S., Oral, A. Y., Guclu, M., Ersoy, C., and Imamoglu, S. (2010) Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients Metab., Clin. Exp. 59, 64-69 10.1016/j.metabol.2009.07.006
92. Koyama, H., Tanaka, S., Monden, M., Shoji, T., Morioka, T., Fukumoto, S., Mori, K., Emoto, M., Shoji, T., Fukui, M., Fujii, H., Nishizawa, Y., and Inaba, M. (2014) Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE) Atherosclerosis 234, 329-334 10.1016/j.atherosclerosis.2014.03.025
93. Akira, K., Amano, M., Okajima, F., Hashimoto, T., and Oikawa, S. (2006) Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits Biol. Pharm. Bull. 29, 75-81 10.1248/bpb.29.75
94. Ishibashi, Y., Yamagishi, S., Matsui, T., Ohta, K., Tanoue, R., Takeuchi, M., Ueda, S., Nakamura, K., and Okuda, S. (2012) Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level Metab., Clin. Exp. 61, 1067-1072 10.1016/j.metabol.2012.01.006
95. Tam, H. L., Shiu, S. W., Wong, Y., Chow, W. S., Betteridge, D. J., and Tan, K. C. (2010) Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes Atherosclerosis 209, 173-177 10.1016/j.atherosclerosis.2009.08.031
96. Cuccurullo, C., Iezzi, A., Fazia, M. L., De Cesare, D., Di Francesco, A., Muraro, R., Bei, R., Ucchino, S., Spigonardo, F., Chiarelli, F., Schmidt, A. M., Cuccurullo, F., Mezzetti, A., and Cipollone, F. (2006) Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes Arterioscler., Thromb., Vasc. Biol. 26, 2716-2723 10.1161/01.ATV.0000249630.02085.12
97. Scharnagl, H., Stojakovic, T., Winkler, K., Rosinger, S., Marz, W., and Boehm, B. O. (2007) The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes Exp. Clin. Endocrinol. Diabetes 115, 372-375 10.1055/s-2007-973830
98. Joshi, D., Gupta, R., Dubey, A., Shiwalkar, A., Pathak, P., Gupta, R. C., Chauthaiwale, V., and Dutt, C. (2009) TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes J. Cardiovasc. Pharmacol. 54, 72-81 10.1097/FJC.0b013e3181ac3a34
99. Chandra, K. P., Shiwalkar, A., Kotecha, J., Thakkar, P., Srivastava, A., Chauthaiwale, V., Sharma, S. K., Cross, M. R., and Dutt, C. (2009) Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects Clin. Drug Invest. 29, 559-575 10.2165/11315260-000000000-00000
100. Zhu, Y., Zhao, Y., Wang, P., Ahmedna, M., and Sang, S. (2015) Bioactive ginger constituents alleviate protein glycation by trapping methylglyoxal Chem. Res. Toxicol. 28, 1842-1849 10.1021/acs.chemrestox.5b00293
101. Li, X., Zheng, T., Sang, S., and Lv, L. (2014) Quercetin inhibits advanced glycation end product formation by trapping methylglyoxal and glyoxal J. Agric. Food Chem. 62, 12152-12158 10.1021/jf504132x
102. Sulston, J. E. and Horvitz, H. R. (1977) Post-embryonic cell lineages of the nematode, Caenorhabditis elegans Dev. Biol. 56, 110-156 10.1016/0012-1606(77)90158-0
103. Sulston, J. E., Schierenberg, E., White, J. G., and Thomson, J. N. (1983) The embryonic cell lineage of the nematode Caenorhabditis elegans Dev. Biol. 100, 64-119 10.1016/0012-1606(83)90201-4
104. White, J. G., Southgate, E., Thomson, J. N., and Brenner, S. (1976) The structure of the ventral nerve cord of Caenorhabditis elegans Philos. Trans. R. Soc., B 275, 327-348 10.1098/rstb.1976.0086
105. Kaletta, T. and Hengartner, M. O. (2006) Finding function in novel targets: C. elegans as a model organism Nat. Rev. Drug Discovery 5, 387-398 10.1038/nrd2031
106. Culetto, E. and Sattelle, D. B. (2000) A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes Hum. Mol. Genet. 9, 869-877 10.1093/hmg/9.6.869
107. Markaki, M. and Tavernarakis, N. (2010) Modeling human diseases in Caenorhabditis elegans Biotechnol. J. 5, 1261-1276 10.1002/biot.201000183
108. Levitan, D. and Greenwald, I. (1995) Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimers disease gene Nature 377, 351-354 10.1038/377351a0
109. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J. F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R. J., Wasco, W., Da Silva, H. A., Haines, J. L., Pericak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommens, J. M., and St George-Hyslop, P. H. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimers disease Nature 375, 754-760 10.1038/375754a0
110. Sundaram, M. and Greenwald, I. (1993) Suppressors of a lin-12 hypomorph define genes that interact with both lin-12 and glp-1 in Caenorhabditis elegans Genetics 135, 765-783
111. Wittenburg, N., Eimer, S., Lakowski, B., Rohrig, S., Rudolph, C., and Baumeister, R. (2000) Presenilin is required for proper morphology and function of neurons in C. elegans Nature 406, 306-309 10.1038/35018575
112. Levitan, D., Doyle, T. G., Brousseau, D., Lee, M. K., Thinakaran, G., Slunt, H. H., Sisodia, S. S., and Greenwald, I. (1996) Assessment of normal and mutant human presenilin function in Caenorhabditis elegans Proc. Natl. Acad. Sci. U. S. A. 93, 14940-14944 10.1073/pnas.93.25.14940
113. De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., and Kopan, R. (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain Nature 398, 518-522 10.1038/19083
114. Ranganathan, R., Sawin, E. R., Trent, C., and Horvitz, H. R. (2001) Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine J. Neurosci. 21, 5871-5884
115. Kullyev, A., Dempsey, C. M., Miller, S., Kuan, C. J., Hapiak, V. M., Komuniecki, R. W., Griffin, C. T., and Sze, J. Y. (2010) A genetic survey of fluoxetine action on synaptic transmission in Caenorhabditis elegans Genetics 186, 929-941 10.1534/genetics.110.118877
116. Ogg, S., Paradis, S., Gottlieb, S., Patterson, G. I., Lee, L., Tissenbaum, H. A., and Ruvkun, G. (1997) The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans Nature 389, 994-999 10.1038/40194
117. Nakae, J., Biggs, W. H., 3rd, Kitamura, T., Cavenee, W. K., Wright, C. V., Arden, K. C., and Accili, D. (2002) Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1 Nat. Genet. 32, 245-253 10.1038/ng890
118. Kenyon, C., Chang, J., Gensch, E., Rudner, A., and Tabtiang, R. (1993) A C. elegans mutant that lives twice as long as wild type Nature 366, 461-464 10.1038/366461a0
119. Kimura, K. D., Tissenbaum, H. A., Liu, Y., and Ruvkun, G. (1997) daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans Science 277, 942-946 10.1126/science.277.5328.942
120. Ayyadevara, S., Alla, R., Thaden, J. J., and Shmookler Reis, R. J. (2008) Remarkable longevity and stress resistance of nematode PI3K-null mutants Aging Cell 7, 13-22 10.1111/j.1474-9726.2007.00348.x
121. Friedman, D. B. and Johnson, T. E. (1988) Three mutants that extend both mean and maximum life span of the nematode, Caenorhabditis elegans, define the age-1 gene J. Gerontol. 43, B102-109 10.1093/geronj/43.4.B102
122. Murphy, C. T. (2006) The search for DAF-16/FOXO transcriptional targets: approaches and discoveries Exp. Gerontol. 41, 910-921 10.1016/j.exger.2006.06.040
123. Hesp, K., Smant, G., and Kammenga, J. E. (2015) Caenorhabditis elegans DAF-16/FOXO transcription factor and its mammalian homologs associate with age-related disease Exp. Gerontol. 72, 1-7 10.1016/j.exger.2015.09.006
124. Schlotterer, A., Kukudov, G., Bozorgmehr, F., Hutter, H., Du, X., Oikonomou, D., Ibrahim, Y., Pfisterer, F., Rabbani, N., Thornalley, P., Sayed, A., Fleming, T., Humpert, P., Schwenger, V., Zeier, M., Hamann, A., Stern, D., Brownlee, M., Bierhaus, A., Nawroth, P., and Morcos, M. (2009) C. elegans as model for the study of high glucose- mediated life span reduction Diabetes 58, 2450-2456 10.2337/db09-0567
125. Shakambari, G., Ashokkumar, B., and Varalakshmi, P. (2015) Phlorotannins from Brown Algae: inhibition of advanced glycation end products formation in high glucose induced Caenorhabditis elegans Indian J. Exp. Biol. 53, 371-379
126. Upadhyay, A., Tuenter, E., Ahmad, R., Amin, A., Exarchou, V., Apers, S., Hermans, N., and Pieters, L. (2014) Kavalactones, a novel class of protein glycation and lipid peroxidation inhibitors Planta Med. 80, 1001-1008 10.1055/s-0034-1382949
127. Golegaonkar, S., Tabrez, S. S., Pandit, A., Sethurathinam, S., Jagadeeshaprasad, M. G., Bansode, S., Sampathkumar, S. G., Kulkarni, M. J., and Mukhopadhyay, A. (2015) Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans Aging Cell 14, 463-473 10.1111/acel.12327
128. Mekheimer, R. A., Sayed, A. A., Ahmed, E. A., and Sadek, K. U. (2015) Synthesis and Characterization of New 1,2,4-Triazolo[1,5-a]pyridines That Extend the Life Span of Caenorhabiditis elegans via Their Anti-Inflammatory/Antioxidant Effects Arch. Pharm. (Weinheim, Ger.) 348, 650-665 10.1002/ardp.201500069
129. Wongchai, K., Schlotterer, A., Lin, J., Humpert, P. M., Klein, T., Hammes, H. P., and Morcos, M. (2016) Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration Horm. Metab. Res. 48, 70-75 10.1055/s-0035-1549876
130. Kang, R., Tang, D., Livesey, K. M., Schapiro, N. E., Lotze, M. T., and Zeh, H. J., 3rd. (2011) The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury Antioxid. Redox Signaling 15, 2175-2184 10.1089/ars.2010.3378
131. Kang, R., Tang, D., Lotze, M. T., and Zeh, H. J., 3rd. (2011) RAGE regulates autophagy and apoptosis following oxidative injury Autophagy 7, 442-444 10.4161/auto.7.4.14681
132. Sessa, L., Gatti, E., Zeni, F., Antonelli, A., Catucci, A., Koch, M., Pompilio, G., Fritz, G., Raucci, A., and Bianchi, M. E. (2014) The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs) PLoS One 9, e86903 10.1371/journal.pone.0086903
133. Chen, P., Burdette, A. J., Porter, J. C., Ricketts, J. C., Fox, S. A., Nery, F. C., Hewett, J. W., Berkowitz, L. A., Breakefield, X. O., Caldwell, K. A., and Caldwell, G. A. (2010) The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response Hum. Mol. Genet. 19, 3502-3515 10.1093/hmg/ddq266
134. Jastrzebska, B., Salom, D., Jin, H., Cao, P., Sun, W., Palczewski, K., and Feng, Z. (2013) Expression of mammalian G protein-coupled receptors in Caenorhabditis elegans Methods Enzymol. 520, 239-256 10.1016/B978-0-12-391861-1.00011-3